Daily Stock Analysis, ADMP, Adamis Pharmaceuticals Corp, priceseries

Adamis Pharmaceuticals Corp. Daily Stock Analysis
Stock Information
Open
3.60
Close
3.45
High
3.60
Low
3.31
Previous Close
3.58
Daily Price Gain
-0.12
YTD High
5.08
YTD High Date
Jan 4, 2018
YTD Low
2.35
YTD Low Date
Feb 22, 2018
YTD Price Change
-1.10
YTD Gain
-24.18%
52 Week High
5.85
52 Week High Date
Oct 23, 2017
52 Week Low
2.35
52 Week Low Date
Feb 22, 2018
52 Week Price Change
-1.95
52 Week Gain
-36.11%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
3.15
Feb 22. 2017
3.32
10 Trading Days
5.44%
Link
LONG
Mar 6. 2017
3.75
Mar 21. 2017
4.34
11 Trading Days
15.80%
Link
LONG
Jun 15. 2017
5.75
Jun 16. 2017
6.10
1 Trading Days
6.09%
Link
LONG
Aug 21. 2017
4.85
Sep 11. 2017
5.23
14 Trading Days
7.75%
Link
LONG
Mar 5. 2018
3.40
Mar 14. 2018
3.61
7 Trading Days
6.25%
Link
LONG
May 15. 2018
4.05
May 30. 2018
4.29
10 Trading Days
5.85%
Link
Company Information
Stock Symbol
ADMP
Exchange
NasdaqCM
Company URL
http://www.adamispharmaceuticals.com
Company Phone
(858) 997-2400
CEO
Dennis J. Carlo
Headquarters
California
Business Address
11455 EL CAMINO REAL, SUITE 310, SAN DIEGO, CA 92130
Sector
-
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0000887247
About

Adamis Pharmaceuticals Corp. is a pharmaceutical company engages in the provision of medical development. Its activities include the combination of specialty pharmaceuticals and biotechnology to produce medicines for patients, and physicians. It focuses on products such as inhaler technology in the field of allergy and respiratory diseases. The company was founded on April 1, 2009 and is headquartered in San Diego, CA.

Description

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. Its specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease; and APC-2000 for the treatment of bronchospasms. The company also has various biotechnology product candidates and technologies, including therapeutic vaccine and cancer product candidates that comprise TeloB-VAX (vaccine), APC-100, APC-200, and APC-300, which are under development for the treatment of prostate cancer. In addition, it operates a 503B drug outsourcing facility that provides prescription medications to patients, physician clinics, hospitals, and surgery centers in the United States. The company is headquartered in San Diego, California.